Review of the efficacy and safety of SGLT2 inhibitors in heart failure patients with low left ventricular ejection fraction without diabetes mellitus

Abstract

Heart failure (HF) with low left ventricular ejection fraction (LVEF) is a disease with an unfavorable prognosis, for the treatment of which there is a need to search for drugs that improve patients’ quality of life. Such a group of drugs is inhibitors of sodium-glucose cotransporter type 2 (iSGLT-2). Purpose of the study: to assess the efficacy and safety of the new class of antihyperglycemic drugs — iSGLT-2.